Schizophrenia Relapse Prevention Clinical Trial
Official title:
Seroquel XR in Schizophrenia Relapse Prevention
| Verified date | November 2010 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Hungary: National Institute of Pharmacy |
| Study type | Observational |
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
| Status | Completed |
| Enrollment | 1600 |
| Est. completion date | July 2010 |
| Est. primary completion date | July 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month Exclusion Criteria: - Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Hungary | Research Site | Baja | |
| Hungary | Research Site | Barcs | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Cegled | |
| Hungary | Research Site | Debrecen | |
| Hungary | Research Site | Dombovar | |
| Hungary | Research Site | Dunaujvaros | |
| Hungary | Research Site | Eger | |
| Hungary | Research Site | Egerszalok | |
| Hungary | Research Site | Emod | |
| Hungary | Research Site | Erd | |
| Hungary | Research Site | Esztergom | |
| Hungary | Research Site | Godollo | |
| Hungary | Research Site | Gyongyos | |
| Hungary | Research Site | Gyor | |
| Hungary | Research Site | Gyula | |
| Hungary | Research Site | Heves | |
| Hungary | Research Site | Hodmezovasarhely | |
| Hungary | Research Site | Janoshalma | |
| Hungary | Research Site | Jaszbereny | |
| Hungary | Research Site | Kalocsa | |
| Hungary | Research Site | Kecskemet | |
| Hungary | Research Site | Ketegyhaza | |
| Hungary | Research Site | Kiskunhalas | |
| Hungary | Research Site | Kistokaj | |
| Hungary | Research Site | Miskolc | |
| Hungary | Research Site | Nagyatad | |
| Hungary | Research Site | Nagykallo | |
| Hungary | Research Site | Nagykanizsa | |
| Hungary | Research Site | Nagykoros | |
| Hungary | Research Site | Oroshaza | |
| Hungary | Research Site | Pecs | |
| Hungary | Research Site | Pomaz | |
| Hungary | Research Site | Satoraljaujhely | |
| Hungary | Research Site | Soltvadkert | |
| Hungary | Research Site | Sopron | |
| Hungary | Research Site | Sumeg | |
| Hungary | Research Site | Szeged | |
| Hungary | Research Site | Szeghalom | |
| Hungary | Research Site | Szekesfehervar | |
| Hungary | Research Site | Szekszard | |
| Hungary | Research Site | Szentes | |
| Hungary | Research Site | Szigetszentmiklos | |
| Hungary | Research Site | Szigetvar | |
| Hungary | Research Site | Szolnok | |
| Hungary | Research Site | Szombathely | |
| Hungary | Research Site | Tatabanya | |
| Hungary | Research Site | Veszprem |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Hungary,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of patients remained relapse free after 6 months of treatment | No | ||
| Secondary | Adherence rate of patients | No | ||
| Secondary | Quality of Life (QoL ) | No |